Orgenesis Inc. | Income Statement

Fiscal year is December-November. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
2,974.00
6,397.00
10,089.00
18,655
Cost of Goods Sold (COGS) incl. D&A
3.30
4.60
5,083.00
9,277.00
8,548.00
13,057
Gross Income
3.30
4.60
2,109.00
2,880.00
1,541.00
5,598
SG&A Expense
5,457.20
4,572.10
4,844.00
8,397.00
11,557.00
21,525
EBIT
5,460.50
4,576.60
6,953.00
-
10,016.00
15,927
Unusual Expense
133.30
180.00
2,338.00
332.00
902.00
50
Non Operating Income/Expense
33.80
404.50
20.00
234.00
2,116.00
1,694
Interest Expense
178.20
703.00
726.00
694.00
1,233.00
2,753
Pretax Income
5,539.20
5,504.10
5,361.00
12,660.00
13,677.00
17,767
Income Tax
-
-
900.00
1,547.00
1,310.00
1,337
Consolidated Net Income
5,539.20
5,504.10
4,461.00
11,113.00
12,367.00
19,104
Net Income
5,539.20
5,504.10
4,461.00
11,113.00
12,367.00
18,291
Net Income After Extraordinaries
5,539.20
5,504.10
4,461.00
11,113.00
12,367.00
18,291
Net Income Available to Common
5,539.20
5,504.10
4,461.00
11,113.00
12,367.00
18,291
EPS (Basic)
1.32
1.34
1.33
15.60
1.31
1.37
Basic Shares Outstanding
4,207.00
4,513.50
4,649.90
710.10
9,680.00
13,374.10
EPS (Diluted)
1.32
1.34
1.33
15.65
1.31
1.37
Diluted Shares Outstanding
4,207.00
4,560.20
4,743.40
710.10
9,714.30
13,374.10
EBITDA
5,457.20
4,572.10
4,962.00
8,354.00
7,120.00
13,303
Equity in Affiliates (Pretax)
-
-
-
123.00
1,214.00
731

About Orgenesis

View Profile
Address
20271 Goldenrod Lane
Germantown Maryland 20876
United States
Employees -
Website http://www.orgenesis.com
Updated 07/08/2019
Orgenesis, Inc. engages in the cell therapy development and manufacturing for advanced medicinal products. It focuses on developing novel and proprietary cell therapy trans-differentiation technologies for the treatment of diabetes. It operates through the Contract Development and Manufacturing Organization (CDMO), and Cellular Therapy Business (CT) segments.